Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
14C-ARN-509 absolute bioavailability and mass balance study in healthy volunteers
NL-OMON38777Active, not recruiting
- Sponsor
- Aragon Pharmaceuticals
- Start
- Mar 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by Aragon Pharmaceuticals. Primary endpoints: Rate and routes of excretion and mass balance, Pharmacokinetics of total radioactivity in plasma and whole blood and 6 more. Started Mar 2013; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON38777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38777.